Organoid modeling of advanced lung cancer tumors

Advanced stage lung cancer represents over 70% of all lung cancers. However, it is largely underrepresented in public genomic cohorts. Markers for treatment prediction and prognosis, as well as new treatment targets are much needed. In this study we will characterize advanced stage lung cancer at multiple omic levels by setting up a library of patient derived organoids. Moreover, we will use the organoids for testing potential treatment targets and for drug screening. The aim is to better understand the mechanisms behind tumor progression and thus improve patient care.